Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MDT-AP-0130

Med · Medulloblastoma

9bb21b79-f610-54b3-af00-3a40bee4a125

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Med
cancer_type_detailed
subtype
Medulloblastoma
cancer_type
Med
subtype
Medulloblastoma
overall_survival_months
52.67999999999999
os_event
true
age_years
11
sex
M
new_clusters
C3
umap1_2d
4.549408914
umap2_2d
5.190484377
umap1_3d
2.798249498
umap2_3d
-1.920014093
umap3_3d
-3.531490867
dataset
Med-Taylor

GSVA pathway preview (0 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

No GSVA scores available for this sample.

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0222
medullo-epn-umap@date-based
MedMedulloblastoma0.927
2302722c6-102e-4b1b-845e-78920380e337
colon-landscapes@1
0.883
3BS_Q13FQ8FV
brain-umap@2
Diffuse intrinsic pontine glioma0.878
4d333233b-e431-462b-ae35-c3b4c6ab3a40
colon-landscapes@1
0.877
5BS_9CA93S6D
brain-umap@2
Diffuse intrinsic pontine glioma0.867
6MDT-AP-0179
medullo-epn-umap@date-based
MedMedulloblastoma0.860
7TCGA-GU-A42R-01A-11R-A23N-07
bladder-landscape@3
0.848
8MDT-AP-0376
medullo-epn-umap@date-based
MedMedulloblastoma0.847
9MDT-AP-0847
medullo-epn-umap@date-based
MedMedulloblastoma0.844
10MBCProject_0719_T1_RNA
breast-umap@18
A0.843

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 7 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
WNT_BETA_CATENIN_SIGNALING0.180Inavolisib— uncovered
KRAS_SIGNALING_DN0.080Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.070Inavolisib— uncovered
G2M_CHECKPOINT0.040Inavolisib— uncovered